OFFICE OF THE SECRETARY OF STATE
LAVONNE GRIFFIN-VALADE
SECRETARY OF STATE

CHERYL MYERS
DEPUTY SECRETARY OF STATE
AND TRIBAL LIAISON

ARCHIVES DIVISION
STEPHANIE CLARK
DIRECTOR

800 SUMMER STREET NE
SALEM, OR 97310
503-373-0701

PERMANENT ADMINISTRATIVE ORDER

FILED
12/19/2023 11:43 AM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

BP 29-2023
CHAPTER 855
BOARD OF PHARMACY

FILING CAPTION: Changes a Pharmacist may make to a Schedule II Prescription

EFFECTIVE DATE: 12/19/2023

AGENCY APPROVED DATE: 12/15/2023

CONTACT: Rachel Melvin
971-673-0001
pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150
Portland,OR 97232

Filed By:
Rachel Melvin
Rules Coordinator

AMEND: 855-080-0085

NOTICE FILED DATE: 10/19/2023

RULE SUMMARY: Permits a Pharmacist to add the patient's address with appropriate verification to the schedule II prescription. Permits a Pharmacist to add the drug strength, dosage form, drug quantity, directions for use, prescriber's address, and prescriber's DEA registration number and to amend or correct the date the prescription was issued and the date the prescription can be filled after consultation and agreement of the prescriber to a schedule II prescription. Requires documentation of amendments or additions. Prohibits changing the patient's name, controlled substance prescribed (except for generic substitution) and the name or signature of the prescriber.

CHANGES TO RULE:

855-080-0085
Prescription Requirements ¶

(1) Registrants, practitioners and Pharmacists as specified therein in the issuance, preparation, labeling, dispensing, recordkeeping and filing of prescriptions for controlled substances must comply with the provisions of 21 CFR 1306.01 (04/01/2022), 21 CFR 1306.02 (04/01/2022), 21 CFR 1306.03 (04/01/2022), 21 CFR 1306.04 (04/01/2022), 21 CFR 1306.05 (04/01/2022), 21 CFR 1306.06 (04/01/2022), 21 CFR 1306.07 (04/01/2022), 21 CFR 1306.08 (04/01/2022), 21 CFR 1306.09 (04/01/2022); 21 CFR 1306.11 (04/01/2022), 21 CFR 1306.12 (04/01/2022), 21 CFR 1306.13 (04/01/2022), 21 CFR 1306.14 (04/01/2022), 21 CFR 1306.15 (04/01/2022); 21 CFR 1306.21 (04/01/2022), 21 CFR 1306.22 (04/01/2022); 21 CFR 1306.23 (04/01/2022), 21 CFR 1306.24 (04/01/2022), 21 CFR 1306.25 (04/01/2022), 21 CFR 1306.27 (04/01/2022); and 21 CFR 1304.03(d) (04/01/2022).¶
(2) Controlled substances listed in 21 CFR 1308.15 (04/01/2022) as schedule V are prescription drugs.¶
(3) Pseudoephedrine and ephedrine may be:¶
(a) Provided to a patient without a prescription under ORS 475.230.¶
(b) Dispensed to patient pursuant to a prescription which must follow the provisions of 21 CFR 1306.21 (04/01/2022), 21 CFR 1306.22 (04/01/2022); 21 CFR 1306.23 (04/01/2022), 21 CFR 1306.24 (04/01/2022), 21 CFR 1306.25 (04/01/2022), and 21 CFR 1306.27 (04/01/2022). ¶
(4) For a Schedule II controlled substance prescription, a Pharmacist may:¶
(a) Add the patient's address based on information provided by the patient or patient's agent with appropriate

verification;¶
(b) Amend or add the following information after consultation with and agreement of the prescriber:¶
(A) Drug strength; ¶
(B) Dosage form;¶
(C) Drug quantity;¶
(D) Directions for use;¶
(E) Prescriber's address; and¶
(F) Prescriber's DEA registration number.¶
(c) Amend the following information after consultation with and agreement of the prescriber, the:¶
(A) Date the prescription was issued; and¶
(B) Date the prescription can be filled.¶
(d) For (b) and (c), the Pharmacist must document on the prescription the date of the prescriber's authorization, the amendment or addition authorized, and the Pharmacist's identity. ¶
(5) For a Schedule II controlled substance prescription, a Pharmacist must not change the patient's name, the controlled substance prescribed except for generic substitution, and the name or signature of the prescriber. ¶
[Publications: Publications referenced are available for review at the agency.]
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 475.185, ORS 475.188